Results 261 to 270 of about 212,078 (304)

Angiotensin Converting Enzyme Inhibitors

American Journal of Hypertension, 1990
This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy.
B L, Herlihy, J T, Herlihy
openaire   +4 more sources

Angiotensin converting enzyme (ACE)

Clinica Chimica Acta, 2022
Angiotensin converting enzyme (ACE) was isolated as a 'hypertensinconverting enzyme'. There have been considerable advances in understanding the metabolic role of ACE in the body. This review attempts to highlight the role of ACE enzyme in the physiological and pathological processes occurring in the organs in which it is localized.The literature was ...
Vatsala Khurana, Binita Goswami
openaire   +2 more sources

Angiotensin-Converting Enzyme Inhibitors

Medical Clinics of North America, 1988
There is convincing evidence that ACE inhibitors, alone or in combination with a diuretic, effectively lower blood pressure in patients with all grades of essential or renovascular hypertension and that they are of particular benefit as adjunctive therapy in patients with congestive heart failure.
H H, Rotmensch, P H, Vlasses, R K, Ferguson   +2 more
openaire   +2 more sources

Angiotensin-Converting Enzyme Inhibitors

AACN Advanced Critical Care, 1992
The angiotensin-converting enzyme (ACE) inhibitors available today include Captopril (Capoten), enalapril (Vasotec), enaloprilat (Vasotec IV), lisinopril (Prinivil, Zestril), benazepril (Lotensin), fosinopril (Monopril), and ramipril (Atace). These drugs are used in the treatment of hypertension and congestive heart failure.
openaire   +2 more sources

Angiotensin converting enzyme inhibitors

Pharmaceutisch Weekblad Scientific Edition, 1982
Inhibition of angiotensin converting enzyme (ACE) in patients suffering from renovascular hypertension results in lowering of the blood-pressure. The development of captopril, an orally active ACE inhibitor and the structure-activity relationship of captopril analogues are described.
openaire   +2 more sources

Angiotensin-Converting Enzyme Inhibitor Angioedema

Advanced Emergency Nursing Journal, 2020
Angioedema from angiotensin-converting enzyme inhibitors (ACEIs) is a potential, emergent, and frightening problem that presents to the emergency department. This article focuses on angioedema caused by using ACEIs. The presentation, pathology, diagnostic testing, treatment, and patient education of angioedema are explored.
Josh, Bankston, David Thomas, House
openaire   +4 more sources

Angiotensin-converting enzyme inhibitors

2001
Publisher Summary Angiotensin-converting enzyme (ACE) inhibitors were first studied clinically in the 1970s. ACE inhibitors were discovered by taking advantage of previous basic research on the physiology of sodium, potassium, and water homeostasis and blood pressure regulation, in a reciprocal way ACE have also advanced research in this field, and ...
J, Menard, A A, Patchett
openaire   +2 more sources

Angiotensin-Converting Enzyme Inhibitors

Medical Clinics of North America, 1987
In summary, ACE inhibitors are effective in reducing blood pressure as initial therapy in some hypertensive patients and in combination with diuretics and other agents in virtually all hypertensives. ACE inhibitors are uniquely advantageous because of their favorable hemodynamic effects, the lack of adverse metabolic effects, and their ability to ...
openaire   +2 more sources

Angiotensin-Converting Enzyme in Neurosarcoidosis

Archives of Neurology, 1987
To the Editor. —We read with great interest the article by Sethi et al in the June 1986 issue of theArchives.1We wish to point out another important aspect of neurosarcoidosis that was not discussed by the authors, namely, determination of angiotensin I—converting enzyme (ACE) levels in the cerebrospinal fluid (CSF) of patients with suspected ...
I, Rubinstein, V, Hoffstein
openaire   +2 more sources

Angiotensin converting enzyme: Substrate inhibition

Peptides, 1989
Phosphate, borate, and Tris inhibit angiotensin converting enzyme (ACE), but HEPES buffer is inert. Measurements of substrate inhibition were made in HEPES buffer at pH 7.0 and 25 degrees C and 37 degrees C. Substrate inhibition was marked and goes to completion.
J R, Schullek, I B, Wilson
openaire   +2 more sources